New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
15:37 EDTGILD, DATA, JKHY, ULTI, HAIN, ATO, BWLD, DV, HI, XOOM, AXS, CVD, AFL, AMP, EQR, CERN, CHRW, UNM, MAC, EW, GNW, GIMONotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Gilead Sciences (GILD), consensus 50c; AFLAC (AFL), consensus $1.39; Ameriprise Financial (AMP), consensus $1.81; Equity Residential (EQR), consensus 69c; Cerner (CERN), consensus 39c; CH Robinson Worldwide (CHRW), consensus 68c; Unum Group (UNM), consensus 84c; Macerich (MAC), consensus 92c; Edwards Lifesciences (EW), consensus 71c; Genworth Financial (GNW), consensus 30c; Covance (CVD), consensus 84c; AXIS Capital (AXS), consensus $1.47; Tableau Software (DATA), consensus 0c; Jack Henry & Associates (JKHY), consensus 60c; Ultimate Software (ULTI), consensus 41c; Hain Celestial (HAIN), consensus 87c; Atmos Energy (ATO), consensus 86c; Buffalo Wild Wings (BWLD), consensus $1.07; DeVry (DV), consensus 73c; Hillenbrand (HI), consensus 52c; Xoom (XOOM), consensus (1c); Gigamon (GIMO), consensus 12c.
News For GILD;AFL;AMP;EQR;CERN;CHRW;UNM;MAC;EW;GNW;CVD;AXS;DATA;JKHY;ULTI;HAIN;ATO;BWLD;DV;HI;XOOM;GIMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 10, 2014
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
10:04 EDTXOOMXoom could be a acquisition of target of PayPal, says Monness Crespi
Subscribe for More Information
10:01 EDTBWLDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 2U (TWOU) initiated with an Outperform at Pacific Crest... Bloomin' Brands (BLMN) initiated with an Outperform at BMO Capital... Brinker (EAT) initiated with a Market Perform at BMO Capital... Buffalo Wild Wings (BWLD) initiated with an Outperform at BMO Capital... Chipotle (CMG) initiated with a Market Perform at BMO Capital... Chuy's (CHUY) initiated with a Market Perform at BMO Capital... Darden (DRI) initiated with a Market Perform at BMO Capital... EMC (EMC) initiated with a Buy at Jefferies... EPR Properties (EPR) initiated with a Buy at BofA/Merrill... HP (HPQ) initiated with a Hold at Jefferies... IBM (IBM) initiated with an Underperform at Jefferies... McDermott (MDR) initiated with an In-Line at Imperial Capital... NetApp (NTAP) initiated with a Hold at Jefferies... New Residential (NRZ) initiated with a Neutral at Piper Jaffray... Nimble Storage (NMBL) initiated with a Buy at Jefferies... Noodles & Company (NDLS) initiated with an Outperform at BMO Capital... PDC Energy (PDCE) initiated with an Overweight at Stephens... Panera Bread (PNRA) initiated with a Market Perform at BMO Capital... Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital... Resource America (REXI) initiated with a Buy at MLV & Co.... Rex Energy (REXX) initiated with an Overweight at Stephens... Seagate (STX) initiated with a Buy at Jefferies... Silicon Motion (SIMO) initiated with a Buy at Brean Capital... Texas Roadhouse (TXRH) initiated with a Market Perform at BMO Capital... W.P. Carey (WPC) initiated with a Neutral at BofA/Merrill... Wayfair (W) initiated with a Buy at Janney Capital...Western Digital (WDC) initiated with a Buy at Jefferies... Yelp (YELP) initiated with a Buy at Sterne Agee.
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
October 9, 2014
16:47 EDTBWLDBuffalo Wild Wings initiated with an Outperform at BMO Capital
Target $165.
11:43 EDTGILDStocks with call strike movement; GILD EWZ
Gilead (GILD) February 120 call option implied volatility increased 3% to 38, MSCI Brazil Index (EWZ) February 58 call option implied volatility increased 3% to 38 according to IVolatility.
10:00 EDTULTIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:28 EDTGILDGilead to be challenged by AbbVie in HCV near-term, says Bernstein
Subscribe for More Information
07:35 EDTULTIUltimate Software initiated with a Buy at MKM Partners
Subscribe for More Information
07:31 EDTMACUBS to hold a tour
Subscribe for More Information
06:25 EDTDVDeVry could close campuses to cut costs, says Deutsche Bank
Subscribe for More Information
October 8, 2014
16:26 EDTGILDOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTGILDOptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
15:49 EDTGILDAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
10:06 EDTCHRWStephens transportation analysts hold an analyst/industry conference call
Subscribe for More Information
07:18 EDTGILDInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use